Fundamental Analysis of NEUROGENE INC(NASDAQ:NGNE) stock

Fundamental Rating

Taking everything into account, NGNE scores 2 out of 10 in our fundamental rating. NGNE was compared to 565 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

NGNE had negative earnings in the past year.

NGNE had a negative operating cash flow in the past year.

In the past 5 years NGNE always reported negative net income.

NGNE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -30.83%, NGNE is in the better half of the industry, outperforming 65.95% of the companies in the same industry.

NGNE has a better Return On Equity (-35.77%) than 75.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	-30.83%
ROE	-35.77%
ROIC	N/A

ROA(3y)-34.38%

ROA(5y)-33.24%

ROE(3y)-41.01%

ROE(5y)-37.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGNE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for NGNE has been increased compared to 1 year ago.

The number of shares outstanding for NGNE has been increased compared to 5 years ago.

NGNE has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.35 indicates that NGNE is not in any danger for bankruptcy at the moment.

The Altman-Z score of NGNE (3.35) is better than 77.18% of its industry peers.

NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

NGNE's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. NGNE outperforms 50.09% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.35

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.17 indicates that NGNE has no problem at all paying its short term obligations.

With an excellent Current ratio value of 12.17, NGNE belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.

NGNE has a Quick Ratio of 12.17. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of NGNE (12.17) is better than 86.10% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.17
Quick Ratio	12.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.80% over the past year.

EPS 1Y (TTM)80.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-17.37%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

NGNE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.12% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y20.95%

EPS Next 2Y9.19%

EPS Next 3Y-0.12%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NGNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.19%

EPS Next 3Y-0.12%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NGNE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (11/20/2024, 8:00:02 PM)

Premarket: 15.05 -0.28 (-1.83%)

15.33

-1.9 (-11.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap227.65M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-30.83%
ROE	-35.77%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	12.17
Quick Ratio	12.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)80.8%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y20.95%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEUROGENE INC (NGNE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens